16.50
2.68%
0.43
Pre-mercato:
16.89
0.39
+2.36%
Precedente Chiudi:
$16.07
Aprire:
$16.2
Volume 24 ore:
57,471
Relative Volume:
0.62
Capitalizzazione di mercato:
$241.65M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-3.2544
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
+5.91%
1M Prestazione:
+1.16%
6M Prestazione:
-40.13%
1 anno Prestazione:
-25.81%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Confronta ANIK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
16.50 | 241.65M | 166.88M | -74.18M | 1.14M | -5.07 |
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-01 | Reiterato | Barrington Research | Outperform |
2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2022-10-14 | Ripresa | Stephens | Equal-Weight |
2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
2021-11-16 | Iniziato | Stephens | Overweight |
2021-07-16 | Iniziato | UBS | Neutral |
2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
2019-11-05 | Iniziato | BWS Financial | Sell |
2019-09-24 | Reiterato | Barrington Research | Outperform |
2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
2017-10-27 | Reiterato | Barrington Research | Outperform |
2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
Facial Aesthetics Market Generated Opportunities, Future - openPR
Orthopedic Digit Implants Market: Share, Revenue Insights, - openPR
Barclays PLC Purchases 13,054 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Viscosupplementation Market Generated Opportunities, Future - openPR
(ANIK) Proactive Strategies - Stock Traders Daily
Anika Therapeutics stock hits 52-week low at $15.8 By Investing.com - Investing.com Australia
Anika Therapeutics stock hits 52-week low at $15.8 - Investing.com India
Jane Street Group LLC Increases Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Geode Capital Management LLC - Defense World
Barclays PLC Buys 13,054 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
We Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business Growth - Yahoo Finance
State Street Corp Sells 7,667 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by HighTower Advisors LLC - Defense World
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Anika Therapeutics to Present at JPM Healthcare Conference 2025: Joint Preservation Leader Takes Stage - StockTitan
(ANIK) On The My Stocks Page - Stock Traders Daily
Fmr LLC Acquires 4,996 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet - Simply Wall St
Anika Therapeutics stock hits 52-week low at $15.99 - Investing.com
Verition Fund Management LLC Sells 1,763 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update - MarketBeat
Knee Osteoarthritis Market Projected CAGR 12.5% Dynamics - openPR
Joint Pain Injection Market Expected to Reach Prominent Growth - openPR
ANIK (Anika Therapeutics) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.
Anika To Participate in December 2024 Investor Conferences - The Manila Times
Anika Therapeutics to Present at Three Major Healthcare Investor Conferences in December | ANIK Stock News - StockTitan
Orthopedic Regenerative Surgical Products Market to Witness - openPR
Joint Pain Injection Market Size, Share, Trends, - openPR
New Strong Sell Stocks for November 11th - Yahoo Canada Finance
Orthobiologics Market Size, Growth, Opportunities 2024-2032 | - openPR
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts - TipRanks
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA - MarketBeat
Anika Therapeutics Announces Third Quarter Financial ResultsOn October 31, 2024, Anika Therapeutics, Inc. released a press statement unveiling its financial outcomes for the third quarter concluding on September 30, 2024. As per the report - Defense World
Viscosupplementation Market Report Analysis, Growth - openPR
Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com - MarketBeat
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript - Insider Monkey
Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $25.00 - Defense World
Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring By Investing.com - Investing.com South Africa
Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring - Investing.com
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates - MSN
Anika Therapeutics (NASDAQ:ANIK) Given New $25.00 Price Target at Barrington Research - MarketBeat
Anika Therapeutics (NASDAQ:ANIK shareholders incur further losses as stock declines 30% this week, taking five-year losses to 72% - Simply Wall St
Anika: Q3 Earnings Snapshot - New Haven Register
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance UK
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline - GuruFocus.com
Anika Therapeutics divests Arthrosurface, eyes Parcus sale - Investing.com India
Anika Therapeutics Focuses on Core Growth Amid Restructuring - TipRanks
Anika Reports Third Quarter 2024 Financial Results - GlobeNewswire
Anika Therapeutics divests Arthrosurface, eyes Parcus sale By Investing.com - Investing.com Canada
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):